Difficulty: Medium
Average Score: 70%
Practice
Which antimicrobial should be avoided in patients of liver disease?
Correct answer
A
Rationale
In the context of drugs and the immune system, it is crucial for healthcare professionals to understand the impact of various antimicrobial agents on different organ systems, especially in patients with liver disease. In this case, the correct answer is option A) Chlortetracycline.
Chlortetracycline is a tetracycline antibiotic that is primarily eliminated through the liver. In patients with liver disease, impaired liver function can lead to decreased drug metabolism and clearance. This can result in drug accumulation, leading to potential toxicity and adverse effects. Therefore, chlortetracycline should be avoided in patients with liver disease to prevent further hepatic damage and minimize the risk of adverse reactions.
Looking at the other options:
- Option B) Cotrimoxazole: While cotrimoxazole is primarily eliminated through the kidneys, it can still potentially cause liver toxicity in some patients. However, it is not as strongly contraindicated in liver disease compared to chlortetracycline.
- Option C) Cephalexin: Cephalexin is primarily excreted through the kidneys and does not pose a significant risk of hepatotoxicity in patients with liver disease.
- Option D) Ethambutol: Ethambutol is primarily cleared through the kidneys and is not known to cause liver damage. It is typically safe to use in patients with liver disease.
Understanding the interactions between drugs and organ systems, such as the liver, is essential for healthcare professionals to make informed decisions and provide safe and effective care to patients. By selecting the appropriate antimicrobial agents based on a patient's liver function, healthcare providers can minimize the risk of adverse effects and optimize treatment outcomes.
Chlortetracycline is a tetracycline antibiotic that is primarily eliminated through the liver. In patients with liver disease, impaired liver function can lead to decreased drug metabolism and clearance. This can result in drug accumulation, leading to potential toxicity and adverse effects. Therefore, chlortetracycline should be avoided in patients with liver disease to prevent further hepatic damage and minimize the risk of adverse reactions.
Looking at the other options:
- Option B) Cotrimoxazole: While cotrimoxazole is primarily eliminated through the kidneys, it can still potentially cause liver toxicity in some patients. However, it is not as strongly contraindicated in liver disease compared to chlortetracycline.
- Option C) Cephalexin: Cephalexin is primarily excreted through the kidneys and does not pose a significant risk of hepatotoxicity in patients with liver disease.
- Option D) Ethambutol: Ethambutol is primarily cleared through the kidneys and is not known to cause liver damage. It is typically safe to use in patients with liver disease.
Understanding the interactions between drugs and organ systems, such as the liver, is essential for healthcare professionals to make informed decisions and provide safe and effective care to patients. By selecting the appropriate antimicrobial agents based on a patient's liver function, healthcare providers can minimize the risk of adverse effects and optimize treatment outcomes.